PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE POTENTIAL-DRUG INTERACTION BETWEEN VENLAFAXINE AND DIAZEPAM

被引:36
|
作者
TROY, SM
LUCKI, I
PEIRGIES, AA
PARKER, VD
KLOCKOWSKI, PM
CHIANG, ST
机构
[1] UNIV PENN,DEPT PSYCHIAT,PHILADELPHIA,PA 19104
[2] UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104
[3] ONEIDA RES SERV INC,WHITESBORO,NY
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 1995年 / 35卷 / 04期
关键词
D O I
10.1002/j.1552-4604.1995.tb04082.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To assess possible pharmacokinetic and pharmacodynamic interactions between the antidepressant venlafaxine and diazepam, a randomized, two-period, crossover study was conducted in 18 men. Multiple-dose venlafaxine (50 mg every 8 hours) or placebo (double-blind) was given for 10 days; on day 4 a single placebo dose (same appearance as diazepam capsule, single-blind) was given; and on day 5 a single dose of diazepam (10 mg) was given. Pharmacokinetic data indicated that diazepam had no significant effect on venlafaxine or O-desmethylvenlafaxine disposition. Diazepam pharmacokinetics were minimally changed in the presence of venlafaxine, Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (V-z/f) increased (0.85 +/- 0.28 Versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng . h/mL; P = .02), Venlafaxine did not alter desmethyldiazepam pharmacokinetics, Pharmacodynamic data showed a statistically significant diazepam-venlafaxine interaction for only one of the eight psychometric tests given. Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments, The observed pharmacokinetic and pharmacodynamic interactions between diazepam and venlafaxine were small and probably clinically insignificant.
引用
收藏
页码:410 / 419
页数:10
相关论文
共 50 条
  • [1] Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol
    Troy, SM
    Turner, MB
    Unruh, M
    Parker, VD
    Chiang, ST
    JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (11): : 1073 - 1081
  • [2] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN SUCRALFATE AND ASPIRIN
    LAU, A
    CHANG, CW
    SCHLESINGER, P
    GASTROENTEROLOGY, 1985, 88 (05) : 1465 - 1465
  • [3] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN SUCRALFATE AND ASPIRIN
    LAU, AH
    CHANG, CW
    SCHLESINGER, PK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 151 - 155
  • [4] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN SUCRALFATE AND ASPIRIN
    LAU, A
    CHANG, CW
    SCHLESINGER, P
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (06): : 457 - 457
  • [5] EVALUATION OF A POTENTIAL-DRUG INTERACTION BETWEEN LEVONORDEFRIN AND CYCLOBENZAPRINE
    NGUYEN, AM
    GAGE, TW
    DORRIS, RL
    JOURNAL OF DENTAL RESEARCH, 1990, 69 : 331 - 331
  • [6] Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach
    Ji, Beihong
    Xue, Ying
    Xu, Yuanyuan
    Liu, Shuhan
    Gough, Albert H.
    Xie, Xiang-Qun
    Wang, Junmei
    ACS CHEMICAL NEUROSCIENCE, 2021, 12 (10): : 1777 - 1790
  • [7] A POTENTIAL-DRUG INTERACTION BETWEEN FLUOXETINE AND VALPROIC ACID
    SOVNER, R
    DAVIS, JM
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1991, 11 (06) : 389 - 389
  • [8] PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION STUDY OF DIAZEPAM AND METOPROLOL
    KLOTZ, U
    REIMANN, IW
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (02) : 223 - 226
  • [9] Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers
    Fleishaker, JC
    Herman, BD
    Pearson, LK
    Ionita, A
    Mucci, M
    CLINICAL DRUG INVESTIGATION, 1999, 18 (02) : 141 - 150
  • [10] Evaluation of the Potential Pharmacokinetic/Pharmacodynamic Interaction between Fluoxetine and Reboxetine in Healthy Volunteers
    Joseph C. Fleishaker
    Beth D. Herman
    Laura K. Pearson
    Antoaneta Ionita
    Massimiliano Mucci
    Clinical Drug Investigation, 1999, 18 : 141 - 150